Stocks making the biggest moves premarket: SNOW, MRNA, AVGO Skip Navigation Markets Business Investing Tech Politics & Policy Video Watchlist Investing Club PRO Livestream Menu Check out the companies making the biggest moves premarket: Snowflake Shares surged 24% after the company's second-quarter results topped analyst expectations. For the quarter, Snowflake posted adjusted earnings of 62 cents per share on revenue of $1.55 billion. Analysts surveyed by LSEG had anticipated 45 cents in earnings per share and $1.48 billion in revenue. The company also raised its full-year product revenue guidance. Software stocks Snowflake's rally lifted its software peers as well. Datadog jumped more than 5%, while ServiceNow was up by 3%. Meanwhile, Salesforce rose just over 1.5%. Hewlett Packard Enterprise The enterprise technology company slipped 3%. HPE is calling for earnings growth of 16% to 20% for the fiscal year ending October 2027, while the FactSet consensus sought a 18.7% increase. Cash flow for the period is expected to be at least %5 billion, versus the Street's forecast for $4.79 billion. Broadcom The chipmaker lost 2.5% as investors responded negatively to the company's revenue forecast for the fourth quarter, which came in at $34.8 billion compared to a $35.03 billion estimate. Fourth quarter non-GAAP operating margin projections came in at 66%, below the 66.5% estimate. Broadcom reported revenue of $29.59 billion for the third quarter and adjusted earnings of $3.32 per share. Campbell's Company The food and beverage company fell almost 7% after it reported earnings guidance for its fiscal year 2027 that came in below expectations. Campbell's expects earnings of between $1.65 and $1.80 per share in fiscal 2027, compared to a FactSet consensus for $1.83 per share. It also forecasted for revenue growth to contract at a wider rate than expected in the fiscal year. Ultragenyx Pharmaceutical Shares plunged more than 46% after the company reported that Phase 3 trial results for its drug to treat Angelman syndrome, a rare genetic neurodevelopmental disorder, did not achieve its primary endpoint. The company said it was disappointed in the result and will evaluate the program to develop the drug, as well as implement significant cost reductions. Petco The pet products retailer jumped almost 9%. Adjusted EBITDA margin in the second quarter came in at 8.2% versus the StreetAccount consensus estimate of 7.4%. Excluding a tariff benefit, the metric came in at 7.7%, which would still beat analysts' expectations. Moderna Shares were off more than 2% after the biotechnology company was downgraded by Rothschild & Co Redburn to sell. Analysts at the firm said the stock, after a huge surge following the success in a trial of its experimental cancer vaccine for melanoma, is now overvalued. Argan The engineering and construction stock popped nearly 7.5% after the company posted better-than-expected earnings and revenue for the second quarter. Argan earned $3.76 per share in the period, well above the $2.64 per share that analysts polled by FactSet had called for. The company's revenue came in at $384 million, while analysts were looking for...
🔥 EXCLUSIVE PARTNER OFFER
Blackview WAVE 10, 8 Go + 128 Go, écran 6,88 pouces, Android 16, processeur octocœur Unisoc UMS9230E, réseau : 4G, OTG (bleu iris)
91.7
🎯 Best price guarantee! Order now and enjoy fast shipping with global tracking.
Affiliate link — Commission earned at no extra cost to you
© EcoNews DZ — Global Economic & Financial News
Comments
Post a Comment